Cost effective preservatives free ophthalmic formulation

https://doi.org/10.53730/ijhs.v6nS4.10256

Authors

Keywords:

ophthalmic, ocular surface disease (OSD), cost effective preservatives

Abstract

The present invention is directed to a method for producing an ophthalmic pharmaceutical formulation containing a carbonic anhydrase inhibitor, hydroxyl ethyl cellulose (HEC), and a beta-adrenergic antagonist for the treatment of ocular hypertension and glaucoma that is free of benzalkonium chloride and other preservatives. The current production technique is a simpler, more cost-effective method of preparing pharmaceutical ophthalmic formulations in a single tank without the usage of extra sterile-filtered tanks. For individuals with newly diagnosed glaucoma, optical therapy is usually the initial line of treatment. Preservatives are essential in all multi-dose ophthalmic drugs to maintain an antibacterial environment in the container, thus eye care professionals must be aware of the effects of preservatives on the ocular surface.

Downloads

Download data is not yet available.

References

De Saint Jean M., et al. “Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells”. Investigative Ophthalmology and Visual Science 40.3 (1999): 619-630.

Fattakhov, N., Normatova, S., Madaminov, S., Tilyakhodzhaeva, G., & Abdulkhakimov, A. (2021). Hirudotherapy as an effective method for treatment of migraine - a disease of unknown etiology. International Journal of Health & Medical Sciences, 4(2), 232-237. https://doi.org/10.31295/ijhms.v4n2.1714

Freeman PD and Kahook MY. “Preservatives in topical ophthalmic medications: historical and clinical perspectives”. Expert Review of Ophthalmology 4.1 (2009): 59-64.

Gayton JL. “Etiology, prevalence, and treatment of dry eye disease”. Clinical Ophthalmology 3 (2009): 405-412.

Ghosh S., et al. “Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication”. Clinical and Experimental Ophthalmology 40.7 (2012): 675-681.

Janine AS. “The epidemiology of dry eye disease: report of the epidemiological subcommittee of the international dry eye workshop”. The Ocular Surface 5.2 (2007): 93-107.

Kaštelan S., et al. “How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome”. BioMed Research International (2013).

Noecker RJ. “Ophthalmic Preservatives: Considerations for Long-term Use in Patients with Dry Eye or Glaucoma”. Review Ophthalmology 8.6 (2010): 1-8.

Noecker RJ., et al. “Corneal and conjunctival changes caused by commonly used glaucoma medications”. Cornea 23.5 (2004): 490-496.

Pisella PJP., et al. “Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication”. British Journal of Ophthalmology 86.4 (2002): 418-423

Skalicky SE., et al. “Ocular surface disease and quality of life in patients with glaucoma”. American Journal of Ophthalmology 153.1 (2012): 1-9.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

Published

03-07-2022

How to Cite

Namdeo, S., & Chhipane, S. (2022). Cost effective preservatives free ophthalmic formulation. International Journal of Health Sciences, 6(S4), 7806–7809. https://doi.org/10.53730/ijhs.v6nS4.10256

Issue

Section

Peer Review Articles